BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19804830)

  • 1. Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.
    Martire A; Ferrante A; Potenza RL; Armida M; Ferretti R; Pézzola A; Domenici MR; Popoli P
    Neurobiol Dis; 2010 Jan; 37(1):99-105. PubMed ID: 19804830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
    Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
    Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
    Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
    Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.
    Ferrante A; Martire A; Armida M; Chiodi V; Pézzola A; Potenza RL; Domenici MR; Popoli P
    Brain Res; 2010 Apr; 1323():184-91. PubMed ID: 20138162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum.
    Tebano MT; Pintor A; Frank C; Domenici MR; Martire A; Pepponi R; Potenza RL; Grieco R; Popoli P
    J Neurosci Res; 2004 Jul; 77(1):100-7. PubMed ID: 15197743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice.
    Cipriani S; Bizzoco E; Gianfriddo M; Melani A; Vannucchi MG; Pedata F
    Exp Neurol; 2008 Sep; 213(1):163-70. PubMed ID: 18586241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
    Gianfriddo M; Melani A; Turchi D; Giovannini MG; Pedata F
    Neurobiol Dis; 2004 Oct; 17(1):77-88. PubMed ID: 15350968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved.
    Martire A; Pepponi R; Domenici MR; Ferrante A; Chiodi V; Popoli P
    J Neurochem; 2013 Apr; 125(2):225-35. PubMed ID: 23363456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
    Tanganelli S; Sandager Nielsen K; Ferraro L; Antonelli T; Kehr J; Franco R; Ferré S; Agnati LF; Fuxe K; Scheel-Krüger J
    Parkinsonism Relat Disord; 2004 Jul; 10(5):273-80. PubMed ID: 15196505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration.
    Minghetti L; Greco A; Potenza RL; Pezzola A; Blum D; Bantubungi K; Popoli P
    J Neuropathol Exp Neurol; 2007 May; 66(5):363-71. PubMed ID: 17483693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
    Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
    Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.
    Popoli P; Blum D; Martire A; Ledent C; Ceruti S; Abbracchio MP
    Prog Neurobiol; 2007 Apr; 81(5-6):331-48. PubMed ID: 17303312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes.
    Ariano MA; Wagle N; Grissell AE
    J Neurosci Res; 2005 Jun; 80(5):634-45. PubMed ID: 15880743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
    Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
    Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.
    Estrada-Sánchez AM; Montiel T; Segovia J; Massieu L
    Neurobiol Dis; 2009 Apr; 34(1):78-86. PubMed ID: 19168136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease.
    Ali NJ; Levine MS
    Dev Neurosci; 2006; 28(3):230-8. PubMed ID: 16679770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat.
    Rebola N; Canas PM; Oliveira CR; Cunha RA
    Neuroscience; 2005; 132(4):893-903. PubMed ID: 15857695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine A 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors.
    Pintor A; Galluzzo M; Grieco R; Pèzzola A; Reggio R; Popoli P
    J Neurochem; 2004 Apr; 89(1):152-6. PubMed ID: 15030399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mice heterozygous for neurotrophin-3 display enhanced vulnerability to excitotoxicity in the striatum through increased expression of N-methyl-D-aspartate receptors.
    Torres-Peraza J; Pezzi S; Canals JM; Gavaldà N; García-Martínez JM; Pérez-Navarro E; Alberch J
    Neuroscience; 2007 Jan; 144(2):462-71. PubMed ID: 17081696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.